Introduction of Cholera Vaccine in Bangladesh

Learn more about:
Related Clinical Trial
First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131) A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131). Immune Response to a Delayed Second Dose of Oral Cholera Vaccine Preventative Intervention for Cholera for 7 Days Impact Study of Cholera Vaccination in Endemic Areas – Clinical Surveillance Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™ in Nepalese Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults PXVX0200 (CVD103-HgR) vs Shanchol in Mali Cholera-Hospital-Based-Intervention-for-7-days A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi Single Dose Azithromycin in the Treatment of Adult Cholera Safety and Immunogenicity of a New Formulation of Euvichol® Cholera Anti-Secretory Treatment Trial PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Zinc Supplementation in Cholera Patients Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Pilot Introduction of Oral Cholera Vaccine in Orissa, India Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200 Immunity to Human Cholera in Bangladesh Ciprofloxacin Multiple Dose for Adult Cholera Effect of Probiotic on Immunogenicity of Oral Cholera Vaccine Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo Protective Immunity to Human Cholera in Bangladesh Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Oral Cholera Vaccine Delivery in Rural Bangladesh Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Mass Oral Cholera Vaccination in Zanzibar Cholera Vaccine Investment Strategy in Bangladesh Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Introduction of Cholera Vaccine in Bangladesh Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Evaluation of a Boosting Regimen With Oral Cholera Vaccine Single Dose Azithromycin to Prevent Cholera in Children Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata

Brief Title

Introduction of Cholera Vaccine in Bangladesh

Official Title

Introduction of Cholera Vaccine in Bangladesh: " Impact Evaluation of Cholera Vaccine and Behaviour Change Interventions in Urban Dhaka"

Brief Summary

      The purpose of this study is to conduct and evaluate the feasibility and effectiveness of a
      mass cholera vaccination program to reduce diarrhea due to Vibrio cholerae in a high
      incidence urban area. This study will also evaluate the feasibility of adding a household
      hand washing and safe drinking water promotion intervention to a cholera vaccine program and
      the overall impact of this combination on decreasing the incidence of diarrhea due to Vibrio

Detailed Description

      Cholera continues to be a major cause of morbidity and mortality in low income countries
      including Bangladesh. It is estimated that there are at least 300,000 severe cases and 1.2
      million infections in people in Bangladesh each year. Deaths annually from cholera may have
      decreased but overall morbidity remains high.

      The project for "Introduction of Cholera Vaccine in Bangladesh" (ICVB) will examine the
      effectiveness of intervention with an oral cholera vaccine in reducing incidence of cholera
      in urban Dhaka, and the effectiveness of a handwashing and home water treatment behaviour
      change intervention in reducing diarrhea due to cholera. The proposal involves evaluation of
      a 2-dose regimen of an oral killed whole cell (WC) vaccine and a handwashing and home water
      treatment behavior change program promoting improved hygiene and home drinking water
      treatment in reducing dehydrating diarrhea in a low income area of Dhaka, Bangladesh. The
      study population will include 90 clusters (neighborhoods) in an area of high cholera
      incidence in Mirpur with a total study population of 240,000. Thirty clusters (approximately
      80,000 people) will receive cholera vaccine alone, 30 clusters will receive both cholera
      vaccine and behavior change and 30 neighborhoods will continue their standard habits and
      practices. Surveillance for cholera and diarrhea will be carried out in all the three areas
      during the whole project period. Following the GIS mapping and census of the target
      populations, the cholera vaccine will be offered to all males and non-pregnant females aged
      one year and above in the vaccination areas, and an aggressive hygiene and safe water
      promotion program will be implemented in the 30 behavior change communication clusters.
      Passive surveillance for cholera will be undertaken using the two ICDDR,B diarrhea treatment
      facilities as well as 10 other health facilities that serve the study areas. Vaccine and
      other public health coverage and costs effectiveness as well cost-benefit will be measured,
      followed by surveillance and identical follow-up studies. The hygiene and safe water behavior
      change program will also be continued for 4 years. The impact of interventions will be
      assessed by following vaccination by directly comparing the incidence of cholera and diarrhea
      in the intervention communities to the incidence in the standard habits and practices

Study Type


Primary Outcome

Number of individuals vaccinated with two dose of oral cholera vaccine.

Secondary Outcome

 Incidence of cholera among vaccinated individuals in vaccination area.





Study Arms / Comparison Groups

 Vaccine arm
Description:  Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

September 2009

Completion Date

December 2016

Primary Completion Date

December 2016

Eligibility Criteria

        Inclusion Criteria:

          1. Apparently healthy residents of selected vaccination sites

          2. Aged 1 year and above

          3. Non-pregnant women

          4. Written informed consent

        Exclusion Criteria:

          1. Age less than 1 year

          2. Pregnant women




1 Year - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

International Centre for Diarrhoeal Disease Research, Bangladesh


 Bill and Melinda Gates Foundation

Study Sponsor

, , 

Verification Date

February 2017